GHK-Cu vs VIP (Vasoactive Intestinal Peptide)
Head-to-head comparison of GHK-Cu and VIP (Vasoactive Intestinal Peptide) for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Ghk Cu | Vip |
|---|---|---|
| Category | Skin & Tissue Repair | Neuropeptide / Reference |
| Mechanism | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. | VIP binds with high affinity to VPAC1 and VPAC2 receptors (Gs-coupled GPCRs), activating adenylyl cyclase and increasing intracellular cAMP. |
| Evidence Rating | F — No Regulatory Activity | B — Phase II/III Clinical Trials |
| Clinical Status | Available in cosmetic formulations; no drug approval | Aviptadil (synthetic VIP) received FDA Emergency Use Authorization consideration for COVID-19 ARDS. Phase II/III trials for ARDS completed. Not FDA-approved for any indication. Investigational for pulmonary hypertension and sarcoidosis. |
| Safety Profile | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin | Very short plasma half-life (~1-2 minutes) limits systemic effects but requires continuous infusion; Hypotension is the primary dose-limiting adverse effect due to potent vasodilation |
| Route | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) | Intranasal (CIRS protocol) or Subcutaneous |
| Dose Range | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area | 50-100 mcg intranasal; higher doses IV in clinical settings |
| Frequency | SC: Once daily; Topical: 1–2x daily | Once daily or as prescribed |
| Molecular Weight | ~403.9 g/mol | ~3326.8 g/mol |
| Half-Life | ~30 minutes plasma | ~1-2 minutes (plasma) |
Overview
GHK-Cu and VIP (Vasoactive Intestinal Peptide) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
VIP (Vasoactive Intestinal Peptide) — Mechanism & Evidence
Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide (MW ~3326.8 g/mol) widely distributed in the central and peripheral nervous systems, lungs, and gastrointestinal tract. It is a potent vasodilator, bronchodilator, and immunomodulator. The synthetic form aviptadil (RLF-100) was investigated for COVID-19-associated acute respiratory distress syndrome (ARDS) and has been studied in pulmonary arterial hypertension. VIP is also used diagnostically in VIPoma identification.
Key claims: Lung-protective effects in ARDS; Potent anti-inflammatory and immunomodulatory; Neuroprotective properties.
Shared Research Applications
These peptides target different research areas. GHK-Cu focuses on Skin Health, Anti-Aging, Wound Healing, while VIP (Vasoactive Intestinal Peptide) targets Pulmonary Research, Immunomodulation Research, Neuroscience Reference.
Safety Considerations
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
VIP (Vasoactive Intestinal Peptide): Very short plasma half-life (~1-2 minutes) limits systemic effects but requires continuous infusion Hypotension is the primary dose-limiting adverse effect due to potent vasodilation Diarrhea and flushing reported at higher doses, consistent with VIP physiology
Shop Research Peptides
GHK-Cu 50mg
50mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
GHK-Cu in Research: Reconstitution, Stability, and Handling Guide
This guide covers the essentials of working with GHK-Cu in a research setting, from reconstitution math and solvent choice to stability and purity considerations. Learn how to handle copper peptides correctly and what to verify before starting a study.
GHK-Cu and Hair Follicle Growth: A Review of Copper Peptide Dermatological Research
Explore the preclinical evidence on GHK-Cu for hair follicle growth, including proposed mechanisms and research limitations.
Synergistic Regeneration: BPC-157, Thymosin Beta-4, and GHK-Cu in Healing Research
Explore the synergistic potential of BPC-157, Thymosin Beta-4, and GHK-Cu in regenerative research. Preclinical evidence and mechanisms reviewed.